The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human immunoglobulin G1 (IgG1) monoclonal antibody, brelovitug, to treat ...

γ-glutamyltransferase and bilirubin levels), and HBV serologies (HBsAg, HBeAg, anti-HBe and anti-HBc antibodies) should be monitored for diagnostic purposes and also to assess response to treatment.

a monoclonal antibody. Notably, those who received nivolumab exhibited higher rates of hepatitis B surface antigen (HBsAg) loss compared to other groups. This is seen as a significant step forward ...

Brelovitug is a fully human immunoglobulin G1 monoclonal antibody that targets hepatitis B virus surface antigen (HBsAG). By binding to HBsAg, brelovitug is expected to neutralize and clear ...

HBsAg levels seem to correlate with HDV viremia in chronic HDV carriers. [51] While recent quality controls have shown good performance of serological assays for anti-HDV antibodies, HDV RNA ...